Robust B-cell Mediated Immunity in COVID-19 Patients

Several recent studies have revealed that SARS-CoV-2 antibodies deplete over time following infection and recovery. Some studies have reported that memory B-cells could provide durable humoral immunity even when serum antibody titers decline. New research has investigated the durability of B-cell immunity following SARS-CoV-2 infection and recovery. The researchers used a sensitive and precise flow-cytometry based assay for quantitating B-cells specific to the SARS-CoV-2 protein receptor-binding domain (S-RBD) as most human antibodies that neutralize viruses target this domain. Multi-dimensional flow cytometric analysis of memory B-cells specific to the S-RBD was performed.

The study included patients which were hospitalized and even those were not hospitalized due to COVID-19. The analysis was performed 39-104 days following the onset of symptoms. S-RBD-specific memory B-cells were found in 13 out of 14 patients. Interestingly, resting memory B-cells constituted the largest proportion of S-RBD-specific memory B-cells. Functional memory marker, FCRL5 was drastically upregulated on S-RBD-specific rMBC, especially in patients with mild disease. The least abundant S-RBD-specific memory B-cells were atypical memory B-cells. This provides evidence of durable B-cell mediated immunity against COVID-19 post-recovery.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://www.medrxiv.org/content/10.1101/2020.10.28.20220996v1

#Featured